Tandem Diabetes to integrate TypeZero’s artificial pancreas tech

Tandem Diabetes Care (NSDQ:TNDM) said today it inked a license agreement with TypeZero Technologies to integrate TypeZero’s artificial pancreas into Tandem’s next-gen t:slim insulin pump.

TypeZero’s artificial pancreas technology includes algorithms developed off of initial research conducted at the University of Virginia, and the company said it has been used in more than 28 clinical studies including more than 475 participants.

“This agreement with TypeZero is a significant step in our shared vision to bring a best-in-class, closed-loop artificial pancreas system to the diabetes community as quickly as possible. We look forward to working with TypeZero on this project to deliver simple-to-use AP solutions that can improve treatment outcomes for people with diabetes,” Tandem Diabetes CEO Kim Blickenstaff said in a press release.

Through the deal, Tandem gains worldwide, non-exclusive rights to use the TypeZero AP tech in future Tandem products, and gives Tandem access to future AP innovations over the next 5 years. The companies said they plan to work together to expedite the clinical research associated with the development of Tandem’s closed-loop AP system.

“Partnering with Tandem to deliver an artificial pancreas device that leverages Tandem’s deep expertise in user-centered design and human factors research is very exciting for the future of diabetes management. We believe that bringing our artificial pancreas technology together with Tandem’s innovative insulin pump platform will revolutionize the way patients manage their diabetes,” TypeZero Tech CEO Chad Rogers said in a prepared statement.

As part of the agreement, a research version of the t:slim insulin pump will be used alongside TypeZero’s AP tech in the International Diabetes Closed Loop Trial scheduled for later this year, which is being funded by the National Institute of Health. Financial details of the deal were not disclosed.

In January, a device developed at the University of Virginia School of Medicine which automatically monitors and regulates blood-sugar level in type 1 diabetes patients began undergoing 2 final clinical trials.

UVA said it was hopeful that the long-term clinical trials would pave the way for FDA clearance of the ‘artificial pancreas’ devices for type 1 diabetes sufferers.

The 1st study, the International Diabetes Closed-Loop trial, is set to test UVA developed technology. The university’s technology has been ‘further refined for clinical use’ by Charlottesville, Va.-based startup TypeZero Technologies, who licensed the technologies.

The post Tandem Diabetes to integrate TypeZero’s artificial pancreas tech appeared first on MassDevice.

from MassDevice http://ift.tt/29WPxVe